The collaboration was initiated when Antleron’s BioScout® custom biomaterial screening was applied to Rousselot’s X-Pure® biomaterial platform. Today, to assist Rousselot in translating its cutting-edge biomaterial innovation, the collaboration has evolved to create a ‘Quality-by-Design’ framework which will be integrated into the X-Pure innovation process.
Commenting on the collaboration, Elke De Clerck, Global R&D Director Rousselot said, “X-Pure–by-Design illustrates that our Antleron-Rousselot® collaborative-development partnership enables both parties to reach further together".
Jan Schrooten, CEO Antleron says: "We are proud to enhance Rousselot’s innovation by developing a translational and risk-based X-Pure roadmap that will support the development of advanced therapy applications".
X-Pure-by-Design encompasses an end-to-end innovation strategy to realize the potential of X-Pure as a novel biomaterial solution for advanced therapy applications. The ‘by-Design’ approach de-risks the X-Pure product portfolio and enables Rousselot to customize its biomaterials to meet customer needs as well as complex biomedical industry requirements, positioning X-Pure as an important component of pioneering workflows for the development of living therapies.
Customizing X-Pure biomaterials in a controlled and application-focused manner is crucial when dealing with patient-specific raw material such as cells. In the dynamic field of advanced therapies, collaborative innovation is important to accelerate the development of new solutions from lab to patient